Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2024 Earnings Call Transcript

We’re particularly encouraged to see the impact of our sales and marketing initiatives that are supporting Sancuso and Vibativ. We’re optimistic about the opportunity to further expand the use of Kristalose in the growing number of states where the product is favorable Medicaid coverage. We’re pleased to share the special report, featuring the use of Caldolor for the treatment of pain and fever across a wide range of patient populations, and we’re thrilled to have expanded Caldolor’s labeling to the youngest of patients. We also believe the special reimbursement associated with the NOPAIN Act can have a meaningful impact on Caldolor’s future growth. And we look forward to providing updates on our further developments as the year progresses.

So that concludes our remarks and let’s open the call to any questions you may have. Operator, please proceed.

Operator: [Operator Instructions]. At this time…

A.J. Kazimi: Well, thank you, everyone.

Operator: Go ahead. Sorry.

A.J. Kazimi: Go ahead.

Operator: I was just going to turn it back to management for any closing remarks. We do have a question that just came up. Let me move them up. I’m seeing an error now. I had a question from Evan and I apologize, it is now not showing.

A.J. Kazimi: Okay. Well, we appreciate everybody who’s joining us for today’s call. And we know many of you prefer a private discussion with management. So please just reach out, and we’re happy to have a follow up and answer any questions you have and hold a discussion. As always, we appreciate your time and interest in Cumberland, and we do look forward to providing another update in the coming months.

Operator: Thank you, sir. Ladies and gentlemen, that concludes today’s call. If you would like to listen to a replay of the discussion, please visit the Investor Relations section on Cumberland’s website. I’d like to thank you for your participation, and you may now disconnect.